PENNINGTON, N.J., Oct. 19, 2017 -- OCEAN POWER TECHNOLOGIES, INC. (NASDAQ:OPTT) (“OPT” OR THE “COMPANY”), today announced the pricing of a best efforts public offering of 5,739,437 shares of its common stock at a price to the public of $1.42 per share. The gross proceeds to the Company from this offering are expected to be approximately $8,150,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on October 23, 2017, subject to customary closing conditions.
Aegis Capital Corp. is acting as the sole placement agent for the offering.
A registration statement on Form S-3 (File No. 333-209517) relating to these securities has been filed with the Securities and Exchange Commission and became effective on April 26, 2016.
The offering will be made only by means of a prospectus supplement and accompanying prospectus. A copy of the prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: [email protected]. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ocean Power Technologies, Inc.
Headquartered in Pennington, New Jersey, OPT is a leader in ocean wave energy conversion. OPT’s proprietary PowerBuoy® technology is based on a scalable and modular design. OPT specializes in cost-effective and environmentally sound ocean wave based power generation and management technology.
Cautionary Statement Regarding Forward Looking Statements
This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will pursue" and similar expressions or variations of such expressions. These forward-looking statements reflect the Company's current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the preliminary prospectus supplement, the accompanying prospectus, and the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
Contact:
Media Contact:
Marilyn Vollrath
Reputation Partners LLC
Phone: (414) 376-8834
Email: [email protected]
Investor Relations Contact:
Andrew Barwicki
Barwicki Investor Relations Inc.
Phone: 516-662-9461


Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 



